Maxim Group Maintains NeuroBo Pharmaceuticals(NRBO.US) With Buy Rating, Maintains Target Price $10
Buy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental Pipeline
Maxim Group Maintains NeuroBo Pharmaceuticals(NRBO.US) With Buy Rating, Maintains Target Price $10
Buy Rating Affirmed for NeuroBo Pharmaceuticals on Strategic Licensing and Promising Clinical Outcomes
Buy Rating Affirmed for NeuroBo Pharmaceuticals on Promising Obesity and MASH Drug Developments
Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target
NeuroBo Pharmaceuticals Analyst Ratings
Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10
NeuroBo Pharmaceuticals Analyst Ratings
No Data